Vermont Lung Center

Colchester, Vermont 05446

1 studies enrolling now · 24 studies all time

What they study most

Asthma, Asthma Acute, Asthma, Exercise Induced, COPD, COPD Acute Exacerbation, Cardiovascular Diseases, Combined Pulmonary Fibrosis and Emphysema, Connective Tissue Diseases, Cystic Fibrosis, Familial Primary Pulmonary Hypertension, Fibrosis, Hypertension

Studies at this site

• Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma) — Running, not enrolling
• A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy — Running, not enrolling
• Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients — Completed
• Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age — Running, not enrolling
• Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis — Running, not enrolling
• Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older — Enrolling by invitation
• A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy — Completed
• A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) — Completed
• PEEP as Rescue Therapy for Asthmatics With Elevated BMI — Completed
• Increased Lung Volume as Controller Therapy for Asthma — Completed
• A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation — Completed
• Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE — Completed
• Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis — Completed
• Study of the Effects of Education on Patients With Chronic Obstructive Pulmonary Disease — Completed
• Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) — Completed
• Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis — Completed
• A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) — Completed
• A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F) — Completed
• A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF) — Stopped early
• Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis — Completed
• Trial of Tauroursodeoxycholic Acid (TUDCA) in Asthma — Stopped early
• Role of Leukotrienes and Adenosine in Hyperpnea-induced Bronchospasm — Completed
• 26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) — Completed